Preliminary studies of acyclovir in chronic hepatitis B.
Three patients with HBsAg-positive and DNA-polymerase-positive chronic hepatitis were treated with increasing dosages of intravenous acyclovir. A fall in DNA polymerase activity was seen with all courses of acyclovir but no dose-response relationship was evident. In only one patient did DNA polymerase fall to zero where it has remained for five months. Two out of 10 courses were associated with significant side effects with the highest dosages of acyclovir but these promptly resolved when the agent was stopped. Acyclovir's apparently partial and transient action suggests that it will not have a role in the treatment of chronic hepatitis B virus infection.
D000212:Acyclovir; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D004259:DNA-Directed DNA Polymerase / Q000378:metabolism; D004341:Drug Evaluation; D006147:Guanine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006509:Hepatitis B / Q000188:drug therapy*; D006515:Hepatitis B virus / Q000201:enzymology; D006801:Humans
D000998:Antiviral Agents; D006147:Guanine; D004259:DNA-Directed DNA Polymerase; D000212:Acyclovir